Rapid health technology assessment of carfilzomib in the treatment of multiple myeloma

FENG Zhen; LAI Ran

doi:10.6039/j.issn.1001-0408.2026.09.20

您当前的位置：

首页 >

文章列表页 >

Rapid health technology assessment of carfilzomib in the treatment of multiple myeloma

更新时间：2026-05-14

- Rapid health technology assessment of carfilzomib in the treatment of multiple myeloma
- ZHONGGUO YAOFANG Vol. 37, Issue 9, Pages: 1222-1228(2026)
- 作者机构：
  
  徐州医科大学附属医院药学部，江苏徐州　221006
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.09.20
  CLC： R979.1;R551.3
- Received：13 October 2025，
  
  Revised：2026-03-25，
  
  Accepted：25 March 2026，
  
  Published：15 May 2026
- 稿件说明：
移动端阅览
冯振,赖冉.卡非佐米治疗多发性骨髓瘤的快速卫生技术评估 [J].中国药房,2026,37(09):1222-1228.

FENG Zhen,LAI Ran.Rapid health technology assessment of carfilzomib in the treatment of multiple myeloma[J].ZHONGGUO YAOFANG,2026,37(09):1222-1228.
冯振,赖冉.卡非佐米治疗多发性骨髓瘤的快速卫生技术评估 [J].中国药房,2026,37(09):1222-1228. DOI： 10.6039/j.issn.1001-0408.2026.09.20.

FENG Zhen,LAI Ran.Rapid health technology assessment of carfilzomib in the treatment of multiple myeloma[J].ZHONGGUO YAOFANG,2026,37(09):1222-1228. DOI： 10.6039/j.issn.1001-0408.2026.09.20.

摘要

目的

综合分析卡非佐米治疗多发性骨髓瘤（MM）的有效性、安全性和经济性，为其临床合理用药提供循证参考。

方法

系统检索PubMed、Embase、the Cochrane Library、Web of Science、中国知网、万方数据库、维普网等数据库，同时涵盖卫生技术评估相关网站，检索时间为建库至2024年12月31日。两位研究者依据预设的纳入与排除标准独立筛选文献，提取数据并评价文献质量，最后对数据进行描述性统计分析。

结果

共纳入21篇文献，包括系统评价/Meta分析7篇、临床试验5篇、药物经济学研究5篇以及卫生技术评估报告4份。有效性分析显示，与对照措施相比，卡非佐米方案可以显著提高总缓解率和临床获益率（

＜0.05），延长无进展生存期并改善患者生活质量（

＜0.05），但对总生存期的影响尚需进一步证实。安全性分析显示，与对照措施相比，卡非佐米方案在周围神经病变风险方面的差异无统计学意义，但心脏毒性和高血压的发生风险显著增加（

＜0.05）。经济性分析显示，卡非佐米方案在美国和欧洲部分国家的二线治疗中具有一定的成本-效益优势，但其经济性受药品价格、给药方案及地区差异影响，在部分国家或三线治疗中可能缺乏优势。

结论

卡非佐米在MM治疗中有效性明确、安全性总体可接受，但需警惕心脏毒性和高血压风险。卡非佐米的治疗价格较高，亟需开展中国人群的药物经济学研究。

Abstract

OBJECTIVE

To comprehensively analyze the effectiveness， safety and economic value of carfilzomib in the treatment of multiple myeloma （MM）， and provide evidence-based guidance for clinical rational drug use.

METHODS

A systematic search was performed in PubMed， Embase， the Cochrane Library， Web of Science， CNKI， Wanfang， VIP， and relevant health technology assessment （HTA） websites， from database inception to December 31， 2024. Two researchers independently screened studies based on predefined inclusion and exclusion criteria， extracted data， and assessed study quality. Descriptive statistical analyses were conducted.

RESULTS

A total of 21 studies were included， comprising 7 systematic reviews/meta-analyses， 5 clinical trials， 5 pharmacoeconomic studies， and 4 HTA reports. Effectiveness analysis indicated that， compared with control groups， carfilzomib significantly improved overall response rate and clinical benefit rate （

＜0.05）， prolonged progression-free survival， and enhanced patient’s quality of life （

＜0.05）， while its impact on overall survival remains to be further confirmed. Safety analysis showed there was no significant difference in the risk of peripheral neuropathy between carfilzomib and controls， while the risks of cardiotoxicity and hypertension were significantly increased （

＜0.05）. Economic analysis suggested that carfilzomib regimens demonstrated certain cost-effectiveness in second-line treatment in the U.S. and some European countries. However， its economic value was influenced by drug price， dosing regimen， and regional differences， and it may lack a cost advantage in some countries or in third-line treatment.

CONCLUSIONS

Carfilzomib shows definite efficacy and generally acceptable safety in the treatment of MM， but cardiotoxicity and hypertension risks require careful monitoring. Given its high treatment cost， pharmacoeconomic studies in the Chinese population are urgently needed.

关键词

Keywords

references

KUMAR S K ， RAJKUMAR V ， KYLE R A ， et al . Multiple myeloma [J ] . Nat Rev Dis Primers ， 2017 ， 3 ： 17046 .

WANG S F ， XU L ， FENG J N ， et al . Prevalence and incidence of multiple myeloma in urban area in China：a national population-based analysis [J ] . Front Oncol ， 2020 ， 9 ： 1513 .

ALLEMANI C ， MATSUDA T ， DI CARLO V ， et al . Global surveillance of trends in cancer survival 2000-14 （CONCORD-3）：analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J ] . Lancet ， 2018 ， 391 （ 10125 ）： 1023 - 1075 .

JAYAWEERA S P E ， WANIGASINGHE KANAKANAMGE S P ， RAJALINGAM D ， et al . Carfilzomib：a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma [J ] . Front Oncol ， 2021 ， 11 ： 740796 .

DIMOPOULOS M A ， MOREAU P ， PALUMBO A ， et al . Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma （ENDEAVOR）：a randomised，phase 3，open-label，multicentre study [J ] . Lancet Oncol ， 2016 ， 17 （ 1 ）： 27 - 38 .

USMANI S Z ， QUACH H ， MATEOS M V ， et al . Carfilzomib，dexamethasone，and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma （CANDOR）：updated outcomes from a randomised，multicentre，open-label，phase 3 study [J ] . Lancet Oncol ， 2022 ， 23 （ 1 ）： 65 - 76 .

SHEA B J ， REEVES B C ， WELLS G ， et al . AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J ] . BMJ ， 2017 ， 358 ： j4008 .

STERNE J A C ， SAVOVIĆ J ， PAGE M J ， et al . RoB 2：a revised tool for assessing risk of bias in randomised trials [J ] . BMJ ， 2019 ， 366 ： l4898 .

SLIM K ， NINI E ， FORESTIER D ， et al . Methodological index for non-randomized studies （minors）：development and validation of a new instrument [J ] . ANZ J Surg ， 2003 ， 73 （ 9 ）： 712 - 716 .

高海亮，卢颖，姜婷婷，等 . 药物经济学评价报告质量评估指南 [J ] . 中国药物经济学， 2019 ， 14 （ 2 ）： 18 - 28 .

HAILEY D . Toward transparency in health technology assessment：a checklist for HTA reports [J ] . Int J Technol Assess Health Care ， 2003 ， 19 （ 1 ）： 1 - 7 .

CHEN R Z ， CHEN B A ， ZHANG X P ， et al . Efficacy of carfilzomib in the treatment of relapsed and （or） refractory multiple myeloma：a meta-analysis of data from clinical trials [J ] . Discov Med ， 2016 ， 22 （ 121 ）： 189 - 199 .

王浩 . 卡非佐米治疗多发性骨髓瘤的效果：系统评价 [D ] . 济南：山东大学， 2017 .

SHAH C ， BISHNOI R ， WANG Y ， et al . Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma：systematic review and meta-analysis of 14 trials [J ] . Oncotarget ， 2018 ， 9 （ 34 ）： 23704 - 23717 .

SHAH C ， BISHNOI R ， JAIN A ， et al . Cardiotoxicity associated with carfilzomib：systematic review and meta-analysis [J ] . Leuk Lymphoma ， 2018 ， 59 （ 11 ）： 2557 - 2569 .

ZHAO F ， YANG B ， WANG J ， et al . Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib [J ] . Drug Des Devel Ther ， 2018 ， 12 ： 1525 - 1531 .

王丹 . 卡非佐米治疗复发性/难治性多发性骨髓瘤的系统评价和Meta分析 [D ] . 太原：山西医科大学， 2019 .

徐彪，冉启杰，李菁媛，等 . 卡非佐米对复发/难治性多发性骨髓瘤的治疗效果的Meta分析 [J ] . 华南国防医学杂志， 2020 ， 34 （ 2 ）： 136 - 140 .

GAY F ， GÜNTHER A ， OFFIDANI M ， et al . Carfilzomib，bendamustine，and dexamethasone in patients with advanced multiple myeloma：the EMN09 phase 1/2 study of the European Myeloma Network [J ] . Cancer ， 2021 ， 127 （ 18 ）： 3413 - 3421 .

VENNER C P ， LEBLANC R ， SANDHU I ， et al . Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma：final results from the MCRN-003/MYX.1 single arm phase Ⅱ trial [J ] . Am J Hematol ， 2021 ， 96 （ 5 ）： 552 - 560 .

YONG K L ， HINSLEY S ， AUNER H W ， et al . Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy：results from a multicenter，phase Ⅱ，randomized，controlled trial （MUKfive） [J ] . Haematologica ， 2021 ， 106 （ 10 ）： 2694 - 2706 .

NINKOVIC S ， HARRISON S J ， LEE J J ， et al . Carfilzomib，thalidomide，and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma：final report of the single-arm，multicenter，phase Ⅱ ALLG MM018/AMN002 study [J ] . Haematologica ， 2024 ， 109 （ 7 ）： 2229 - 2238 .

PERROT A ， DELIMPASI S ， SPANOUDAKIS E ， et al . An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib，pomalidomide，and dexamethasone （KPd）：SELECT study [J ] . Leuk Lymphoma ， 2024 ， 65 （ 6 ）： 833 - 842 .

JAKUBOWIAK A J ， CAMPIONI M ， BENEDICT Á ， et al . Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective [J ] . J Med Econ ， 2016 ， 19 （ 11 ）： 1061 - 1074 .

JAKUBOWIAK A J ， HOUISSE I ， MÁJER I ， et al . Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States [J ] . Expert Rev Hematol ， 2017 ， 10 （ 12 ）： 1107 - 1119 .

PELLIGRA C G ， PARIKH K ， GUO S E ， et al . Cost-effectiveness of pomalidomide，carfilzomib，and daratumumab for the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma in the United States [J ] . Clin Ther ， 2017 ， 39 （ 10 ）： 1986 - 2005.e5 .

CAMPIONI M ， AGIRREZABAL I ， HAJEK R ， et al . Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data [J ] . Eur J Health Econ ， 2020 ， 21 （ 2 ）： 219 - 233 .

GOUDARZI Z ， SHAHTAHERI R S ， NAJAFPOUR Z ， et al . Cost-effectiveness and budget impact analysis of Daratumumab，Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma [J ] . Cost Eff Resour Alloc ， 2024 ， 22 （ 1 ）： 17 .

Austrian Institute for Health Technology Assessment . Carfilzomib （Kyprolis ® ） for patients with relapsed multiple myeloma who have received one to three prior lines of therapy [EB/OL ] .[ 2025-11-15 ] . https：//eprints.aihta.at/1070/ https://eprints.aihta.at/1070/ .

Canada’s Drug and Health Technology Agency . Kyprolis for multiple myeloma （relapsed）：details [EB/OL ] . [ 2025-04-07 ] . https：//www.cadth.ca/kyprolis-multiple-myeloma-relapsed-details https://www.cadth.ca/kyprolis-multiple-myeloma-relapsed-details .

National Institute for Health and Care Excellence . Carfilzomib for previously treated multiple myeloma [EB/OL ] . [ 2025-04-07 ] . https：//www.nice.org.uk/guidance/ta657 https://www.nice.org.uk/guidance/ta657 .

National Institute for Health and Care Excellence . Carfilzomib with dexamethasone and lenalidomide for pre- viously treated multiple myeloma [EB/OL ] .[ 2025-04-07 ] . https：//www.nice.org.uk/guidance/ta695 https://www.nice.org.uk/guidance/ta695 .

PROSKURIAKOVA E ， JADA K ， KAKIEU DJOSSI S ， et al . Mechanisms and potential treatment options of heart failure in patients with multiple myeloma [J ] . Cureus ， 2021 ， 13 （ 6 ）： e15943 .

MINA S A ， MUHSEN I N ， BURNS E A ， et al . Post-marketing analysis of peripheral neuropathy burden with new-generation proteasome inhibitors using the FDA adverse event reporting system [J ] . Turk J Haematol ， 2021 ， 38 （ 3 ）： 218 - 221 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of current situation of researches on comprehensive evaluation of drugs in China based on CiteSpace

Rapid Health Technology Assessment of Donepezil in the Treatment of Alzheimer ’s Disease

Rapid Health Technology Assessment of Albumin-bound Paclitaxel in the Treatment of Breast Cancer

Effectiveness，Safety and Economy of Evolocumab in the Treatment of Hypercholesterolemia ：A Rapid Health Technology Assessment

Rapid Health Technology Assessment of Tirofiban in the Treatment of Acute Coronary Syndrome

Related Author

XIAO Misu

ZHANG Jianping

YANG Quanjun

GUO Cheng

ZHANG Tian

LI Ting

WU Lili

PEI Yifang

Related Institution

Dept. of Anesthesiology， the Affiliated Hospital of Xuzhou Medical University

Dept. of Dermatology， the Affiliated Hospital of Xuzhou Medical University

The First Clinical Medical College， Henan University of Chinese Medicine

Dept. of Spleen， Stomach and Hepatobiliary Disease， the First Affiliated Hospital of Henan University of CM

Dept. of Dermatology，the First Affiliated Hospital of Nanyang Medical College

⁰